Hans Edgar Bishop
CIK 1480212 · CEO & President · last filed 2026-07-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$28.32M
Companies
6
Total Filings
72
Lifetime Open-Market Net
-$34.48M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SANA | Director | 5,854,800 | $3.68 | $21.55M | $0 | 27 | 2026-07-07 |
| LYEL | Director | 234,281 | $13.55 | $3.17M | $0 | 7 | 2024-06-17 |
| A | Director | 24,226 | $148.45 | $3.60M | $0 | 9 | 2024-03-19 |
| CELGENE CORP /DE/ (CELGZ) Delisted | Director | 0 | — | — | $0 | 3 | 2019-11-22 |
| Juno Therapeutics, Inc. (JUNO) Delisted | CEO & President | 135,452 | — | — | -$34.48M | 17 | 2018-03-07 |
| AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Director | 93,350 | — | — | $0 | 3 | 2014-02-14 |
Recent Filings · Page 7 of 8
72 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-02-04 | Juno Therapeutics, Inc. (JUNO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-12-17 | Juno Therapeutics, Inc. (JUNO) Delisted | Mixed | −37,500 | -$3.84M | EDGAR |
| 2015-03-05 | Juno Therapeutics, Inc. (JUNO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-02-14 | AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Grant (A) | +28,900 | $0 | EDGAR |
| 2013-02-19 | AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Grant (A) | +19,450 | $0 | EDGAR |
| 2012-05-25 | AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Grant (A) | +45,000 | $0 | EDGAR |
| 2011-08-02 | — | Tax (F) | −2,291 | -$86.3K | |
| 2011-05-03 | — | Tax (F) | −2,342 | -$99.0K | |
| 2011-02-11 | — | Tax (F) | −9,229 | -$323.1K | |
| 2011-01-24 | — | Grant (A) | +28,051 | $0 |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.